CSR Analysis MaaT Pharma
maatpharma.comDevelopment of microbiome therapeutics to improve cancer treatment outcomes through immune modulation.
Development of microbiome therapeutics to improve cancer treatment outcomes through immune modulation.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Priothera
B
Development of innovative therapies for hematological malignancies, focusing on immune modulators to enhance outcomes in allogeneic hematopoietic cell transplantation and CAR T cell therapy.
Transgene
A
Development of innovative immunotherapies against cancer using advanced genetic engineering and artificial intelligence technologies.
Biocodex
B
Development and provision of pharmaceutical solutions focusing on microbiota care, women's health, and orphan diseases.
Initiatives identified among leaders
Amélioration de la qualité de vie au travail
“Biocodex a amélioré la qualité de vie au travail p...” - BiocodexAlignement avec les objectifs de développement durable
“Transgene s'aligne avec les objectifs de développe...” - TransgeneÉgalité des genres et développement durable
“Biocodex a obtenu un score de 93/100 à l'indice de...” - Biocodex26% of similar organizations communicate on CSR issues
+226 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports
